Semaglutide S5 GLP-1 Agonist
The 5mg compounded formulation of semaglutide — the GLP-1 receptor agonist FDA-approved as Wegovy and Ozempic.
Book Free ConsultationCall 310.299.4444What Semaglutide S5 actually is
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The STEP trials demonstrated mean weight loss of 14.9% at 68 weeks in adults with obesity on once-weekly subcutaneous semaglutide, the largest weight-loss effect of any FDA-approved pharmacotherapy at the time.1
At Luxbae we prescribe semaglutide in 5mg, 10mg, and 20mg vials from licensed compounding pharmacies, titrated to tolerability and weight-loss goal. The 5mg dose is our starting concentration suited to the early titration phase. Mechanism: central appetite suppression via hypothalamic GLP-1 receptors plus delayed gastric emptying.2
At Luxbae, Semaglutide S5 is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.
Mechanism — Central appetite plus gut signaling
GLP-1 receptor agonism in hypothalamic appetite centers reduces food intake; peripheral effects slow gastric emptying.2
What the research shows
Weight loss. Mean 14.9% body-weight loss at 68 weeks in STEP-1 trial.1
Cardiovascular outcomes. Major-event reduction documented in SELECT trial.3
Glycemic control. Robust A1C reduction in T2D populations.
Side effects: Nausea, constipation, occasional vomiting (especially during titration), fatigue, rare injection-site reactions.
FDA note: Semaglutide is FDA-approved as Ozempic (T2D), Wegovy (obesity), and Rybelsus (oral T2D). Compounded formulations are available where shortage rules apply and are prescribed under physician supervision.
Semaglutide S5 FAQ
Compounded vs brand?
Compounded is bioequivalent semaglutide from licensed pharmacies, prescribed when shortages or cost barriers apply.
How much weight will I lose?
STEP-1 mean was 14.9% at 68 weeks. Individual response varies widely.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metab. 2018;27(4):740-756.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity. N Engl J Med. 2023;389(24):2221-2232.